CONCLUSIONS GLP-1-RAs may provide clinical benefits for patients with IIH, improving outcomes and reducing the need for invasive interventions
People with GI sensitivity If you have a history of GI issues, whether from previous GLP-1 agonist use, conditions like IBS or GERD, or general digestive sensitivity, starting at the absolute lowest dose is critical
The companies are also pledging to repatriate foreign revenues and guarantee MFN pricing on all future (and some existing) products, giving state Medicaid programs access to these lower, globally competitive drug costs
approval is plausible 2027 to 2028
A measurable, short-term decrease in total testosterone levels
Pancreatitis: Cases of pancreatitis have been reported